IRS1 and cancer: Given the differences between IRS1/2 and IRS4 at the molecular level, knowledge of the signaling pathways controlled by IRS4 may enable the design of new drugs for the treatment of cancer without causing deleterious effects on the regulation of insulin and/or IGF1 signaling cascades.